© 1999 American Heart Association, Inc.
Thrombosis |
Tissue Plasminogen Activator (tPA) Deficiency Exacerbates Cerebrovascular Fibrin Deposition and Brain Injury in a Murine Stroke Model
Studies in tPA-Deficient Mice and Wild-Type Mice on a Matched Genetic Background
From the Department of Neurosurgery (P.T., L.W., S.Y., M.H.W., B.V.Z.), University of Southern California, Los Angeles; the Neuroscience Center (N.S.), University of Colorado Health Sciences Center, Denver; the Division of Neurosurgery (J.G.M., B.V.Z.), Children’s Hospital Los Angeles, University of Southern California, Los Angeles; Scripps Research Institute (J.H.G.), La Jolla, Calif; and the Center for Transgene Technology and Gene Therapy (P.C.), Flanders, Leuven, Belgium.
Correspondence to Berislav V. Zlokovic, MD, PhD, 2025 Zonal Ave, RMR 506, Los Angeles, CA 90033. E-mail zlokovic{at}hsc.usc.edu
Abstract—Although the serine protease, tissue plasminogen activator (tPA), is approved by the US Food and Drug Administration for therapy to combat focal cerebral infarction, the basic concept of thrombolytic tPA therapy for stroke was challenged by recent studies that used genetically manipulated tPA-deficient (tPA-/-) mice, which suggested that tPA mediates ischemic neuronal damage. However, those studies were potentially flawed because the genotypes of tPA-/- and wild-type control mice were not entirely clear, and ischemic neuronal injury was evaluated in isolation of tPA effects on brain thrombosis. Using mice with appropriate genetic backgrounds and a middle cerebral artery occlusion stroke model with nonsiliconized thread, which does lead to microvascular thrombus formation, in the present study we determined the risk for cerebrovascular thrombosis and neuronal injury in tPA-/- and genetically matched tPA+/+ mice subjected to transient focal ischemia. Cerebrovascular fibrin deposition and the infarction volume were increased by 8.2- and 6.7-fold in tPA-/- versus tPA+/+ mice, respectively, and these variables were correlated with reduced cerebral blood flow up to 58% (P<0.05) and impaired motor neurological score by 70% (P<0.05). Our findings indicate that tPA deficiency exacerbates ischemia-induced cerebrovascular thrombosis and that endogenous tPA protects the brain from an ischemic insult, presumably through its thrombolytic action. In addition, our study emphasizes the importance of appropriate genetic controls in murine stroke research.
Key Words: tissue plasminogen activator • cerebrovascular events • fibrin • neuroprotection • ischemia
This article has been cited by other articles:
 |
|
 |
|
  J. Iwanami, M. Mogi, J.-M. Li, K. Tsukuda, L.-J. Min, A. Sakata, T. Fujita, M. Iwai, and M. Horiuchi Deletion of Angiotensin II Type 2 Receptor Attenuates Protective Effects of Bone Marrow Stromal Cell Treatment on Ischemia-Reperfusion Brain Injury in Mice * Supplemental Materials and Methods Stroke, September 1, 2008; 39(9): 2554 - 2559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Adhami, D. Yu, W. Yin, A. Schloemer, K. A. Burns, G. Liao, J. L. Degen, J. Chen, and C.-Y. Kuan Deleterious Effects of Plasminogen Activators in Neonatal Cerebral Hypoxia-Ischemia Am. J. Pathol., June 1, 2008; 172(6): 1704 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Orset, R. Macrez, A. R. Young, D. Panthou, E. Angles-Cano, E. Maubert, V. Agin, and D. Vivien Mouse Model of In Situ Thromboembolic Stroke and Reperfusion Stroke, October 1, 2007; 38(10): 2771 - 2778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Paul, S. Strickland, and J. P. Melchor Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease J. Exp. Med., August 6, 2007; 204(8): 1999 - 2008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Hafer-Macko, F. M. Ivey, J. D. Sorkin, and R. F. Macko Microvascular tissue plasminogen activator is reduced in diabetic neuropathy Neurology, July 17, 2007; 69(3): 268 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Atkinson, H. Zhu, F. Qiao, J. C. Varela, J. Yu, H. Song, M. S. Kindy, and S. Tomlinson Complement-Dependent P-Selectin Expression and Injury following Ischemic Stroke J. Immunol., November 15, 2006; 177(10): 7266 - 7274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-H. Liang and D.-M. Chuang Differential Roles of Glycogen Synthase Kinase-3 Isoforms in the Regulation of Transcriptional Activation J. Biol. Chem., October 13, 2006; 281(41): 30479 - 30484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Wilczak, J. W. Elting, D. Chesik, I. P. Kema, and J. De Keyser Intravenous Tissue Plasminogen Activator in Patients With Stroke Increases the Bioavailability of Insulin-Like Growth Factor-1 Stroke, September 1, 2006; 37(9): 2368 - 2371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J.T.H. Roelofs, K. M.A. Rouschop, J. C. Leemans, N. Claessen, A. M. de Boer, W. M. Frederiks, H.R. Lijnen, J. J. Weening, and S. Florquin Tissue-Type Plasminogen Activator Modulates Inflammatory Responses and Renal Function in Ischemia Reperfusion Injury J. Am. Soc. Nephrol., January 1, 2006; 17(1): 131 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Jood, P. Ladenvall, A. Tjarnlund-Wolf, C. Ladenvall, M. Andersson, S. Nilsson, C. Blomstrand, and C. Jern Fibrinolytic Gene Polymorphism and Ischemic Stroke Stroke, October 1, 2005; 36(10): 2077 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Reddrop, R. X. Moldrich, P. M. Beart, M. Farso, G. T. Liberatore, D. W. Howells, K.-U. Petersen, W.-D. Schleuning, and R. L. Medcalf Vampire Bat Salivary Plasminogen Activator (Desmoteplase) Inhibits Tissue-Type Plasminogen Activator-Induced Potentiation of Excitotoxic Injury Stroke, June 1, 2005; 36(6): 1241 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yepes and D. A. Lawrence New Functions for an Old Enzyme: Nonhemostatic Roles for Tissue-Type Plasminogen Activator in the Central Nervous System Experimental Biology and Medicine, December 1, 2004; 229(11): 1097 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.N. Atochin, J.C. Murciano, Y. Gursoy-Ozdemir, T. Krasik, F. Noda, C. Ayata, A.K. Dunn, M.A. Moskowitz, P.L. Huang, and V.R. Muzykantov Mouse Model of Microembolic Stroke and Reperfusion Stroke, September 1, 2004; 35(9): 2177 - 2182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Iwai, H.-W. Liu, R. Chen, A. Ide, S. Okamoto, R. Hata, M. Sakanaka, T. Shiuchi, and M. Horiuchi Possible Inhibition of Focal Cerebral Ischemia by Angiotensin II Type 2 Receptor Stimulation Circulation, August 17, 2004; 110(7): 843 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Melchor, R. Pawlak, and S. Strickland The Tissue Plasminogen Activator-Plasminogen Proteolytic Cascade Accelerates Amyloid-{beta} (A{beta}) Degradation and Inhibits A{beta}-Induced Neurodegeneration J. Neurosci., October 1, 2003; 23(26): 8867 - 8871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Ellsworth, R. Garcia, J. Yu, and M. S. Kindy Fibroblast Growth Factor-18 Reduced Infarct Volumes and Behavioral Deficits After Transient Occlusion of the Middle Cerebral Artery in Rats Stroke, June 1, 2003; 34(6): 1507 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Liu, H. Guo, J. H. Griffin, J. A. Fernandez, and B. V. Zlokovic Protein S Confers Neuronal Protection During Ischemic/Hypoxic Injury in Mice Circulation, April 8, 2003; 107(13): 1791 - 1796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Singh, K.G. Burnand, M. Collins;, A. Luttun, D. Collen, B. Boelhouwer;, and A. Smith Failure of Thrombus to Resolve in Urokinase-Type Plasminogen Activator Gene-Knockout Mice: Rescue by Normal Bone Marrow-Derived Cells Circulation, February 18, 2003; 107(6): 869 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Liberatore, A. Samson, C. Bladin, W.-D. Schleuning, and R. L. Medcalf Vampire Bat Salivary Plasminogen Activator (Desmoteplase): A Unique Fibrinolytic Enzyme That Does Not Promote Neurodegeneration Stroke, February 1, 2003; 34(2): 537 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Niessen, T. Hilger, M. Hoehn, and K.-A. Hossmann Thrombolytic Treatment of Clot Embolism in Rat: Comparison of Intra-arterial and Intravenous Application of Recombinant Tissue Plasminogen Activator Stroke, December 1, 2002; 33(12): 2999 - 3005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang, L. Zhang, M. Yepes, Q. Jiang, Q. Li, P. Arniego, T. A. Coleman, D. A. Lawrence, and M. Chopp Adjuvant Treatment With Neuroserpin Increases the Therapeutic Window for Tissue-Type Plasminogen Activator Administration in a Rat Model of Embolic Stroke Circulation, August 6, 2002; 106(6): 740 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Kilic, M. Bahr, and D. M. Hermann Effects of Recombinant Tissue Plasminogen Activator After Intraluminal Thread Occlusion in Mice: Role of Hemodynamic Alterations Stroke, November 1, 2001; 32(11): 2641 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shibata, S. R. Kumar, A. Amar, J. A. Fernandez, F. Hofman, J. H. Griffin, and B. V. Zlokovic Anti-Inflammatory, Antithrombotic, and Neuroprotective Effects of Activated Protein C in a Murine Model of Focal Ischemic Stroke Circulation, April 3, 2001; 103(13): 1799 - 1805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yepes, M. Sandkvist, M. K. K. Wong, T. A. Coleman, E. Smith, S. L. Cohan, and D. A. Lawrence Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis Blood, July 15, 2000; 96(2): 569 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Kudryk, A. Bini, S. R. Kumar, and B. V. Zlokovic Monoclonal Antibody Designated T2G1 Reacts With Human Fibrin {beta}-Chain but Not With the Corresponding Chain From Mouse Fibrin Arterioscler. Thromb. Vasc. Biol., July 1, 2000; 20(7): 1848 - 1849. [Full Text] [PDF]
|
|
|
|
|
|
C. D. Sigmund Viewpoint: Are Studies in Genetically Altered Mice Out of Control? Arterioscler. Thromb. Vasc. Biol., June 1, 2000; 20(6): 1425 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg On Ischemic Brain Injury in Genetically Altered Mice Arterioscler. Thromb. Vasc. Biol., November 1, 1999; 19(11): 2581 - 2583. [Full Text] [PDF]
|
|